by Paola Romecín  , Joaquin García-Estañ  and Noemí M. Atucha

Received: 15 May 2019;  Published: 01 November 2019;  doi: 10.21926/obm.hg.1904039

(1) Background: Platelet function is commonly altered in liver cirrhosis. In experimenta models of liver cirrhosis we have analyzed the mechanisms of this defective function. (2) Methods: Experiments were performed in a model of liver cirrhosis by bile duct-ligation in washed platelets by means of fluorescence spectroscopy with fura-2. (3) Results: We have found several alterations compatible with the existence of a hyperaggregatory state. These alterations are related to a defective platelet calcium handling, spec [...]

by Priya R. Bhosale  , Oliver H. Wang  and Jeannelyn S. Estrella

Received: 08 July 2019;  Published: 28 October 2019;  doi: 10.21926/obm.hg.1904038

Background: Pure pancreatic-type ACC outside the pancreas is extremely rare. Methods: We presented a very rare case of primary ACC of the pancreatic-type involving jejunum with a synchronous metastasis to left adrenal gland arising in well-developed ectopic pancreas which had fully developed pancreatic acini, islets of Langerhans, ductal structures, pancreatic cancer precursor lesions and a well-formed minor papilla that opens to the mucosal surface of jejunum. We also reviewed all 21 cases of pure pancreatic-type [...]

by Laura Alonso Canal  , María José Quiles Blanco  , David Jiménez Leiva  and María José González Iglesias

Received: 26 June 2019;  Published: 30 September 2019;  doi: 10.21926/obm.hg.1903037

Alopecia areata is an autoimmune disease of unknown origin. It has been proposed that it is a multifactorial disease with genetic, immunological, infectious, circulatory, and psychogenic factors being involved in its etiopathogenesis. Its association with other autoimmune diseases is frequent. The infection of Helicobacter pylori has been linked to multiple immuno-mediated extradigestive conditions including alopecia areata. There is scientific evidence of the usefulness of naltrexone in low doses (an opioid antago [...]

by Herbert Van Kruiningen

Received: 05 April 2019;  Published: 30 September 2019;  doi: 10.21926/obm.hg.1903036

by Alessandro Luigi Rossi  , Vincenzo Capilupi  , David Palombo  , Luigi Tagliatesta  , Tecla Terenzio  , Marco Vitali  and Matteo Chiapasco

Received: 29 April 2019;  Published: 30 August 2019;  doi: 10.21926/obm.hg.1903035

OBJECTIVES To review current literature analysing possible secondary complications in response to the administration of paracetamol and codeine as analgesics in the dental field. To discuss a case of secondary acute pancreatitis triggered by the administration of both active ingredients. MATERIALS AND METHODS A 28-year-old patient, without any pancreatic or hepatobiliary condition was diagnosed with acute pancreatitis 3 hours after taking paracetamol 500mg and codeine 30mg prescribed as pain-relief therapy after ex [...]

by Mauro Turrin

Received: 15 March 2019;  Published: 29 August 2019;  doi: 10.21926/obm.hg.1903034

Background: Among the rarest causes of acute pancreatitis, in addition to the drugs (DIAP), there are eosinophilic pancreatitis (EP) and autoimmune pancreatitis (AIP). Methods: we have researched on PUBMED the descriptions of clinical cases of eosinophilic pancreatitis appeared from 1990 to February 2019 and those related to new drugs responsible for acute pancreatitis. Results: we found about thirty reports of eosinophilic pancreatitis associated or not with hypereosinophilia and gastro-intestinal manifestations. [...]

by Alina Wong  and Scott D Lee

Received: 09 May 2019;  Published: 16 August 2019;  doi: 10.21926/obm.hg.1903033

Crohn’s disease is characterized by chronic intestinal inflammation that can result in significant morbidity and loss of intestinal function over time. Many novel treatments for Crohn’s disease are being developed, but a significant portion of patients still requires surgical therapy for structuring or penetrating disease. While the utility of esophagogastroduodenoscopy and ileocolonoscopy in inflammatory bowel disease patients is well established, new endoscopic techniques are being developed to help evaluate prev [...]

by Abdulmaleek Sado  , Rahul Kalla  and Simon Campbell

Received: 20 May 2019;  Published: 14 August 2019;  doi: 10.21926/obm.hg.1903032

Crohn's disease is part of a group of diseases termed inflammatory bowel disease. Guidelines have long advocated the use of steroids for acute flare up and Current goals of treatment include enhancing long-lasting remission, preventing relapse, reducing the need for surgery, preventing complications and slowing disease progression. No cure currently exists for the disease. Traditionally, the clinical approach to treatment has been symptom-based where patients have had to ‘earn’ their next treatment escalation. Howe [...]

by Rachel Rutherford  and Patrick B Allen

Received: 25 February 2019;  Published: 12 August 2019;  doi: 10.21926/obm.hg.1903031

Crohn's Disease (CD) is a chronic inflammatory, relapsing and remitting condition that leads to structural damage of the bowel wall. It can be located in any part of the gastrointestinal tract with associated extra-intestinal manifestations. It varies in severity having many complications resulting in significant morbidity. In the past decade medical management of CD has evolved rapidly and with ongoing research it continues to show promising novel therapies. In this article we aim to give an overview of current li [...]

by Marta Ramirez  and Mercedes Fernandez

Received: 25 February 2019;  Published: 31 July 2019;  doi: 10.21926/obm.hg.1903030

This review describes our current understanding of the pathogenic role of angiogenesis in chronic liver disease and portal hypertension, emphasizing its involvement not only in the liver but also in extrahepatic complications such as the formation of portosystemic collaterals and increased splanchnic blood flow, and highlighting different molecular and cellular mechanisms involved.